Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Erlinge

Showing results (171-180 of 489) with videos related to

Pageof 49
Sort By:
International Journal of Cardiology|December 5, 2018
Air pollution in relation to very short-term risk of ST-segment elevation myocardial infarction: Case-crossover analysis of SWEDEHEARTAnders Sahlén, Petter Ljungman, David Erlinge, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|October 3, 2025
A Vessel-Specific Analysis of Deferred Lesions Using the Instantaneous Wave-Free Ratio and Fractional Flow ReserveKarolina Berntorp, Moman A Mohammad, Sasha Koul, et al.
European Heart Journal. Acute Cardiovascular Care|September 2, 2017
Editor's Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trialSofia Karlsson, Pontus Andell, Moman A Mohammad, et al.
Circulation|July 5, 2024
Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort StudyChristian Reitan, Pontus Andell, Joakim Alfredsson, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 18, 2016
The Rationale for and Clinical Pharmacology of Prasugrel 5 mgJoseph A Jakubowski, David Erlinge, Dimitrios Alexopoulos, et al.
Journal of Cardiovascular Pharmacology|February 3, 2023
Statin Treatment Intensity, Discontinuation, and Long-Term Outcome in Patients With Acute Myocardial Infarction and Impaired Kidney FunctionMasih Khedri, Karolina Szummer, Pia Lundman, et al.
Psychiatry Research|February 8, 2017
Troponin T levels associated with genetic variants in NOTCH2 and MTNR1B in women with psychosisDzana Sudic Hukic, Catharina Lavebratt, Eric Olsson, et al.
Thrombosis Research|September 25, 2018
Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary interventionDimitrios Venetsanos, Tomas L Lindahl, Sofia Sederholm Lawesson, et al.
European Heart Journal|July 21, 2016
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registryAnders Sahlén, Christoph Varenhorst, Bo Lagerqvist, et al.
RMD Open|April 10, 2024
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern SwedenPavlos Stamatis, Moman Aladdin Mohammad, Karl Gisslander, et al.
Pageof 49

Showing results (171-180 of 489) with videos related to

Sort By:
Pageof 49
International Journal of Cardiology|December 5, 2018
Air pollution in relation to very short-term risk of ST-segment elevation myocardial infarction: Case-crossover analysis of SWEDEHEARTAnders Sahlén, Petter Ljungman, David Erlinge, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|October 3, 2025
A Vessel-Specific Analysis of Deferred Lesions Using the Instantaneous Wave-Free Ratio and Fractional Flow ReserveKarolina Berntorp, Moman A Mohammad, Sasha Koul, et al.
European Heart Journal. Acute Cardiovascular Care|September 2, 2017
Editor's Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trialSofia Karlsson, Pontus Andell, Moman A Mohammad, et al.
Circulation|July 5, 2024
Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort StudyChristian Reitan, Pontus Andell, Joakim Alfredsson, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 18, 2016
The Rationale for and Clinical Pharmacology of Prasugrel 5 mgJoseph A Jakubowski, David Erlinge, Dimitrios Alexopoulos, et al.
Journal of Cardiovascular Pharmacology|February 3, 2023
Statin Treatment Intensity, Discontinuation, and Long-Term Outcome in Patients With Acute Myocardial Infarction and Impaired Kidney FunctionMasih Khedri, Karolina Szummer, Pia Lundman, et al.
Psychiatry Research|February 8, 2017
Troponin T levels associated with genetic variants in NOTCH2 and MTNR1B in women with psychosisDzana Sudic Hukic, Catharina Lavebratt, Eric Olsson, et al.
Thrombosis Research|September 25, 2018
Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary interventionDimitrios Venetsanos, Tomas L Lindahl, Sofia Sederholm Lawesson, et al.
European Heart Journal|July 21, 2016
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registryAnders Sahlén, Christoph Varenhorst, Bo Lagerqvist, et al.
RMD Open|April 10, 2024
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern SwedenPavlos Stamatis, Moman Aladdin Mohammad, Karl Gisslander, et al.
Pageof 49